TY - JOUR
T1 - Subphenotypes in critical care
T2 - translation into clinical practice
AU - Reddy, Kiran
AU - Sinha, Pratik
AU - O'Kane, Cecilia M.
AU - Gordon, Anthony C.
AU - Calfee, Carolyn S.
AU - McAuley, Daniel F.
N1 - Funding Information:
CMO'K reports grants from Innovate UK in collaboration with Randox for the PHIND trial, and grants from the UK National Institute for Health Research (NIHR), Wellcome Trust, and other funders for studies investigating treatments for ARDS; her spouse has received personal fees from GlaxoSmithKline, Boehringer Ingelheim, Bayer, Quench Bio, and GEn1E Lifesciences for consultancy on ARDS, outside of the submitted work. ACG reports an NIHR Research Professorship grant; personal fees and non-financial support from Orion Corporation (Orion Pharma); grants and other support from Tenax Therapeutics; and support from Bristol-Meyers Squibb and GlaxoSmithKline, outside of the submitted work. CSC reports grants from the US National Institutes of Health; grants and personal fees from Bayer; grants from GlaxoSmithKline; and personal fees from Roche (Genentech), Prometic, CSL Behring, and Quark, outside of the submitted work. DFM reports a grant from Innovate UK in collaboration with Randox for the PHIND trial; and personal fees for consultancy from GlaxoSmithKline, Boehringer Ingelheim, Bayer, Quench Bio, and GEn1E Lifesciences, outside of the submitted work. His institution, Queen's University Belfast, has received funds through grants from the NIHR, Wellcome Trust, Innovate UK, and other sources. He is one of four named inventors on a patent covering the use of sialic acid-bearing nanoparticles as anti-inflammatory agents issued to his institution (US8962032), which had no direct bearing on the content of this Review. DFM is a director of research for the Intensive Care Society and a director for the NIHR Efficacy and Mechanism Programme. All other authors declare no competing interests.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/6
Y1 - 2020/6
N2 - Despite progress in the supportive care available for critically ill patients, few advances have been made in the search for effective disease-modifying therapeutic options. The fact that many trials in critical care medicine have not identified a treatment benefit is probably due, in part, to the underlying heterogeneity of critical care syndromes. Numerous approaches have been proposed to divide populations of critically ill patients into more meaningful subgroups (subphenotypes), some of which might be more useful than others. Subclassification systems driven by clinical features and biomarkers have been proposed for acute respiratory distress syndrome, sepsis, acute kidney injury, and pancreatitis. Identifying the systems that are most useful and biologically meaningful could lead to a better understanding of the pathophysiology of critical care syndromes and the discovery of new treatment targets, and allow recruitment in future therapeutic trials to focus on predicted responders. This Review discusses proposed subphenotypes of critical illness syndromes and highlights the issues that will need to be addressed to translate subphenotypes into clinical practice.
AB - Despite progress in the supportive care available for critically ill patients, few advances have been made in the search for effective disease-modifying therapeutic options. The fact that many trials in critical care medicine have not identified a treatment benefit is probably due, in part, to the underlying heterogeneity of critical care syndromes. Numerous approaches have been proposed to divide populations of critically ill patients into more meaningful subgroups (subphenotypes), some of which might be more useful than others. Subclassification systems driven by clinical features and biomarkers have been proposed for acute respiratory distress syndrome, sepsis, acute kidney injury, and pancreatitis. Identifying the systems that are most useful and biologically meaningful could lead to a better understanding of the pathophysiology of critical care syndromes and the discovery of new treatment targets, and allow recruitment in future therapeutic trials to focus on predicted responders. This Review discusses proposed subphenotypes of critical illness syndromes and highlights the issues that will need to be addressed to translate subphenotypes into clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85085945459&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(20)30124-7
DO - 10.1016/S2213-2600(20)30124-7
M3 - Review article
C2 - 32526190
AN - SCOPUS:85085945459
SN - 2213-2600
VL - 8
SP - 631
EP - 643
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 6
ER -